TG Therapeutics reported second-quarter 2025 financial results with total revenue of $141.1 million, including $138.8 million from BRIUMVI U.S. net revenue. The company raised its full-year 2025 BRIUMVI U.S. net product revenue guidance to $570 million to $575 million, up from a prior guidance of $560 million. Net income was $28.2 million for the quarter and $33.2 million for the first six months of 2025. Twist Bioscience announced fiscal third-quarter 2025 results, reporting revenue of $96.1 million and net income of $20.4 million, marking a return to profitability driven by strength in next-generation sequencing and an expanded synthetic biology portfolio. However, Twist revised its 2025 revenue outlook to $374 million to $376 million, resulting in a share price decline. Madrigal Pharmaceuticals reported second-quarter 2025 Rezdiffra net sales of $212.8 million, with over 23,000 patients on the drug as of June 30, 2025. The company holds $802 million in cash and cash equivalents and received a new U.S. patent for Rezdiffra extending protection to February 4, 2045. Galaxy Digital posted second-quarter 2025 net income of $30.7 million and adjusted EBITDA of $211 million, up from a negative $290 million in the prior quarter, with total assets increasing 43% quarter-over-quarter to $9.1 billion. Despite these gains, Galaxy Digital shares fell following missed revenue and earnings targets. Gilead Sciences reported second-quarter 2025 revenue of $7.08 billion, beating estimates, and adjusted EPS of $2.01. Biktarvy sales rose 9% year-over-year to $3.5 billion, and the company secured FDA approval for Yeztugo, the first twice-yearly HIV pre-exposure prophylaxis (PrEP). Gilead raised its full-year outlook following strong HIV drug sales. Patient reports indicate positive outcomes for BRIUMVI in multiple sclerosis treatment, with some patients switching from Kesimpta and other therapies to BRIUMVI.